Spurious increase in erythrocyte mean corpuscular volume (MCV) on automated cell analyzers is a well-characterized lab error in hypertonic patients. A difference between automated and manual MCV (dMCV) greater than 2fl has been shown to predict hypertonicity in humans. The purpose of this study was to investigate dMCV as a marker for serum hypertonicity in dogs and 2 to examine the relationship between dMCV and three methods of estimating serum tonicity: measured (OsM M ), calculated (OsM C ), and calculated effective (OsM CE ) osmolalities. OsM C , OsM CE , and dMCV were calculated from routine blood values and OsM M was directly measured in 121 dogs. The dMCV of hypertonic dogs was significantly larger than that of normotonic dogs for all three osmolality methods. dMCV predicted hypertonicity as estimated by OsM M better than it predicted hypertonicity as estimated by OsM C and OsM CE . A cut-off of 2.96fl yielded the best sensitivity (76%) and specificity (71%) for hypertonicity estimated by OsM M .
Introduction
Serum hypertonicity is an important clinical problem in both human and veterinary medicine. Hypertonicity, also known as effective hyperosmolality, is defined as an elevated serum concentration of solutes that draw fluid out of cells by osmosis (i.e.
effective osmoles or osmoles with tonic effect) (Wellman et al. 2012) . At a tissue level, hypertonicity can lead to cellular dysfunction by altered function of the protein macromolecular apparatus, decreased protein synthesis, changes in cell membrane function, and breaks in nucleic acid strands (Garner and Berg 1994; Lang et al. 1998; Alfieri and Petronini 2007) . At a systemic level, hypertonicity is associated with a variety of clinical conditions and has been investigated as an early indicator for progression of several disease states (Stookey et al. 2007a; Stookey 2005; Clegg et al. 2013; Stookey et al. 2004a; Stookey et al. 2004b; Schemerhorn and Barr 2006; Kotas et al. 2008 ).
In the Third National Health and Nutrition Examination Survey (NHANES III), a cross-sectional survey of nonhospitalized individuals, the prevalence of hypertonicity (OsM ≥ 300 mOsM) in human adults in the U.S. is estimated at 20% with borderline hypertonicity (OsM = 295-300 mOsM) affecting an additional 40% of the population (Stookey 2005) . Higher prevalence has been associated with age, obesity, race, and diabetic status (Stookey et al. 2007a; Stookey 2005) . Hypertonicity may also be an early indicator for frailty, a condition of decreased functional reserve of the body and vulnerability to systemic morbidity, especially common in the elderly (Stookey et al. 2004b , Clegg et al. 2013 . A longitudinal study of older adults found that plasma hypertonicity was an independent predictor for the onset of disability within a four-year period and mortality within an eightyear period (Stookey et al. 2004b) . Hypertonicity is particularly important clinical problem for insulin-resistant and diabetic patients. In NHANES III, the prevalence of hypertonicity in human diabetics (identified by fasting glucose or oral glucose tolerance test or by self-reporting by the subject) was reported as 35-78% (Stookey 2005) . In human hyperglycemic, pre-diabetic patients, hypertonicity has been shown to be a risk factor for progression to diabetes mellitus, with hypernatremia having an independent effect on disease progression (Stookey et al. 2004a ).
In diabetic dogs and cats, the prevalence of effective hyperosmolality was reported as 81% (Schemerhorn and Barr 2006) . Interestingly, in diabetic animals, sodium (Na) concentrations appear to be highly associated with osmolality (tonicity), emphasizing the importance of this solute in diabetic patients (Schemerhorn and Barr 2006, Kotas et al. 2008 (Wellman et al. 2012 ).
Because it is impractical to measure every solute with known or possible tonic effect, true tonicity is almost impossible to hypertonicity and, when combined with elevated plasma vasopressin levels, yielded 100% sensitivity and specificity (Stookey et al. 2007b ).
Use of dMCV to detect hypertonicity has not been investigated in veterinary patients. The purpose of the present study was to investigate dMCV as a marker for serum hypertonicity in dogs and to examine the relationship between dMCV and three methods of estimating serum tonicity: OsM M , OsM C , and OsM CE . It was hypothesized that dMCV would be a useful marker for hypertonicity and that an elevated dMCV would predict hypertonicity estimated by OsM CE better than it would predict hypertonicity estimated by OsM M or OsM C . hct using a microcentrifuge and card hct reader was included as a standard part of the CBC. Biochemistry profiles were performed using the COBAS C501 Chemistry Analyzer. c Serum samples
Materials and Methods

Cases -
were then frozen at -20°C until identified for use in the study at which point they were transferred to a -80°C freezer where they were stored until batch osmometry measurements could be made. OsM C (Eq. 1) and OsM CE (Eq. 2) were determined using standard clinical formulas (Wellman et al. 2012) .
Eq. 1 ( )
Eq. 2 ( )
The dMCV (Eq. 3) was calculated by as previously reported (Stookey et al. 2007b ).
Eq. 3
Data Analysis -Continuous data are represented as median and range. dMCV data were assessed for normality using the was calculated for each osmolality method and these were compared.
A post hoc analysis was performed to establish a dMCV cut-off for mild hypertonicity, defined as OsM M ≥ 300 mOsM.
The dMCV of normosmolar (OsM M < 300 mOsM) and hyperosmolar (OsM M ≥ 300 mOsM) dogs were compared using a Student's t-test; an ROC curve was generated and a cut-off value maximizing sensitivity and specificity was visually determined.
All statistical analyses were performed using commercial software. e A p-value less than 0.05 was considered statistically significant.
e Excel, Microsoft; Redmond, WA
Results
Two hundred and eighty-nine cases were identified from the records search (n = 255) or previously recorded (n = 34 Figure 2) ; a dMCV cut-off of 1.49 fl yielded a 75% sensitivity and 76% specificity.
Discussion
The results of this study support the hypothesis that dMCV can be used as a physiologic marker for hypertonicity in hospitalized canine patients. This finding was anticipated because red blood cells acclimated in a hypertonic solution (i.e. patient plasma) swell when placed into isotonic solution (i.e. cell analyzer media). Interestingly, dMCV predicted serum hypertonicity best when tonicity was estimated using measured osmolality (OsM M ≥ 320 mOsM) rather than calculated effective osmolality (OsM CE ).
This differs from the original hypothesis: it was suspected that dMCV would be a better marker for OsM CE because, as a In this study, dogs were divided into normosmolar and hyperosmolar groups using 320 mOsM as a cut-off for OsM M , OsM C , and OsM CE . This value was initially chosen in order to include only dogs with clinically relevant hypertonicity in the hyperosmolar group. However, in certain situations, it may be useful to identify mild hypertonicity as is the case in humans in whom it was shown that mild hypertonicity (OsM M ≥ 300 mOsM) was a risk factor for frailty in the elderly and for progression of disease in pre-diabetic patients (Stookey et al. 2004b; Stookey et al. 2004a) . Therefore, the canine data was reexamined to determine dMCV performance when mild hyperosmolality is present. Using a lower cut-off for dMCV ( ≥ 1.5 fl) for mild hypertonicity (OsM M ≥ 300 mOsM) performed as well as the higher dMCV cut-off (≥ 3 fl) did for overt hypertonicity (OsM M ≥ 320 mOsM). This gradated cut-off system may be useful in future longitudinal studies investigating disease progression or markers for various morbidities.
It is important to recognize that RBC size is not solely governed by tonicity, so changes in erythrocyte volume in response to hyper-or hypotonicity are complex and may be different than anticipated. Part of this phenomenon may be due to the biconcave shape of the mammalian erythrocyte. Changes in cell volume alter the conformation of the erythrocyte cytoskeleton leading to a change in cell membrane cell curvature (Wong 2006) . Therefore, if cell volume is derived from measurements of cell diameter, volume may be underestimated. In the present study, RBCs were subjected to 'sphering' treatment to produce homogenous spheres by the cell analyzer prior to analysis, so biconcave structural effects were eliminated. The sphering technique is standard practice for most RBC analyzers and has been shown to render accurate and repeatable measurements of RBC size (Kim and Ornstein 1983) . Plasma and intracellular proteins exert an effect on fluid balance through oncotic pressure, which varies according to size, structure, and charge of the protein moieties. Because changes in net oncotic pressure can elicit fluid shifts independently of tonicity, plasma protein concentrations may alter cell size (in either direction) from values predicted based on plasma tonicity alone (Wellman et al. 2012) . Albumin is the most important plasma determinant of oncotic pressure, contributing approximately 80% of the total plasma colloid osmotic pressure (Wellman et al. 2012) . Finally, and most importantly, all mammalian cells have the ability to regulate volume through a variety of active processes, which allow the cell to acclimate during periods of osmotic stress as well as participate in a variety of metabolic functions (Lang et al. 1998; Alfieri and Petronini 2007; Haussinger 1996; Schliess et al. 2007 ). The cellular compensation for hypertonic-induced cell shrinkage is termed regulatory volume increase (RVI) and the response to hypotonicinduced cell swelling, regulatory volume decrease (RVD) (Alfieri and Petronini 2007; Schliess et al. 2007) . Early responses to cell shrinkage or swelling include increased membrane ion transport followed by transport of small non-ionic organic molecules (osmolytes) including alcohols, methylamines, and amino acids.
These compensatory mechanisms precipitate a partial RVI or RVD within seconds to minutes of initial fluid shifts. The late response to tonic change involves activation (or inhibition) of a variety of cellular pathways that lead to the production of heat shock proteins and to novel synthesis of intracellular osmolytes. These processes require up-or down-regulation of gene expression, so complete volume compensation (RVI or RVD), if it occurs, takes hours to days (Lang et al. 1998) . In this study, cell volume (MCV M ) was measured using an automatic cell analyzer, which completes its analysis within seconds. Therefore, it can be expected that any compensatory volume regulatory changes would be incomplete and measured cell volume would still reflect initial fluid shifts cause by tonic insult to the cells.
There are several limitations to the present study. First, the determinants of dMCV (hct, RBC, and MCV M ) were measured in plasma, whereas osmolality, electrolyte, BUN, and glucose measurements were made in serum, which may have affected associations between dMCV and the various methods of estimating tonicity. Ideally, all measurements would have been made in plasma because plasma is a better representation of the in vivo environment; however, serum is the preferred sample type for measurement of electrolytes and plasma samples were not available at the time of sample retrieval for most dogs (Stockham and Scott 2008b) . Another concern is that prolonged storage of frozen samples could introduce artifact in the measurement of serum osmolality. To the authors' knowledge, stability of frozen canine serum for osmometric analysis has not been reported.
However, a prospective study that examined dMCV and serum osmolality using fresh samples analyzed concurrently showed results similar to those reported here; therefore, the present results are likely valid (Reinhart, unpublished) . In this study, all blood samples were collected during SA-ICU hospitalization, but timing of collection was not standardized. It is likely that some patients received treatment prior to sample collection; the number and degree of interventions performed prior to collection also likely varied among patients. This limitation does not weaken the ability of dMCV to predict hypertonicity, but the summary data presented for dMCV, osmolality, and various clinicopathologic values should not be considered representative of a general SA-ICU population at admission. Ideally, all blood collection would have been performed at presentation prior to treatment; however, this was precluded by retrospective nature of the study. Similarly, the dogs in this study are a heterogeneous population of various breeds, ages, and disease processes. Future studies could include assessment of tonicity in specific disease states such as diabetes mellitus; in general survey populations stratified by breed, sex, or age; in hospitalized populations stratified by disease category or severity; or in longitudinal studies tracking changes in tonicity over time, with disease progression, or during treatment.
In conclusion, the results of this study support the use of dMCV (≥ 3 fl) a physiologic marker for overt serum hypertonicity (OsM M ≥ 320 mOsM) in dogs. dMCV predicts hypertonicity estimated by measured osmolality better than by either calculated method, suggesting the influence of unmeasured effective osmoles in serum on dMCV. ^This value is unlikely to be the true osmolality of the sample, as a serum osmolality of 510 mOsM is incompatible with life, and likely represents technical error. However, this value was repeatable using the freezing-point depression osmometer so was included in the data set. Exclusion of this data point does not significantly alter the results of this study. 
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